Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease
- 1 August 2005
- journal article
- case report
- Published by Wiley in American Journal of Hematology
- Vol. 79 (4), 337-339
- https://doi.org/10.1002/ajh.20418
Abstract
Two human immunodeficiency virus-infected patients who needed etoposide therapy to control exacerbations of Castleman disease received four infusions of rituximab. Clinical and virologic relapses with increased blood human herpesvirus-8 DNA levels occurred in both patients 4 and 24 weeks later and were associated with a worsening of Kaposi sarcoma.Keywords
This publication has 9 references indexed in Scilit:
- Multicentric Castleman's diseaseAIDS, 2004
- Rituximab therapy for HIV-associated Castleman diseaseBlood, 2003
- Prolonged remission of HIV-associated multicentric Castelmanʼs disease with an anti-CD20 monoclonal antibody as primary therapyAIDS, 2003
- Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximabBlood, 2002
- Long-term remission of Kaposi sarcoma–associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapyBlood, 2001
- Treatment of HIV-associated multicentric Castleman's disease with oral etoposideAmerican Journal of Hematology, 2001
- High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patientsBlood, 2000
- Multicentric Castlemanʼs disease in HIV infectionAIDS, 1996
- Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease [see comments]Blood, 1995